In silico/in vitro study of hybrid D-modified steroidal alkylator anticancer activity using uridine phosphorylase as target protein

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 831-842

  Geromichalos, George D ^a   Geromichalou, Elena ^b   Camoutsis, Charalambos ^c   Kontos, Michael ^d   Dalezis, Panagiotis ^a   Papageorgiou, Athanasios ^a   Grivas, Anastasios A ^e   Tsigris, Christos ^d   Trafalis, Dimitrios T ^f  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hybrid steroidal alkylators; In silico molecular docking; In vitro assay; Mitrogen mustards; Pancreatic cancer cells; Uridine phosphorylase

Indexed keywords

3BETA HYDROXY 13ALPHA AMINO 13,17 SECO 5ALPHA ANDROSTAN 17 OIC 13,17 LACTAM [P [N,N BIS(2 CHLOROETHYL)AMINO]PHENYL]ACETATE; 3BETA HYDROXY 17 OXO 17ALPHA OXA 5ALPHA ANDROSTAN [P [N,N BIS (2 CHLOROETHYL)AMINO]PHENYL]ACETATE; 3BETA HYDROXY 5ALPHA ANDROSTAN [P [N,N BIS (2 CHLOROETHYL)AMINO]PHENYL]ACETATE; ALKYLATING AGENT; CYTOSTATIC AGENT; CYTOTOXIC AGENT; STEROID; UNCLASSIFIED DRUG; URIDINE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; COLORIMETRY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; STEROIDS; THERMODYNAMICS; THIOURACIL; URIDINE PHOSPHORYLASE;

EID: 79956142333     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Camoutsis C and Trafalis DT: An overview on the antileukemic potential of D-homo-aza- and respective 17 beta-acetamido- steroidal alkylating esters. Invest New Drugs 21(1): 47-54, 2003. (Pubitemid 36628484)
2. Trafalis DT, Geromichalos GD, Koukoulitsa C, Papageorgiou A, Karamanakos P and Camoutsis C: Lactandrate: a D-homo-azaandrosterone alkylator in the treatment of breast cancer. Breast Cancer Res Treat 97(1): 17-31, 2006.
3. Trafalis DT: Hybrid aza-steroid alkylators in the treatment of colon cancer. Cancer Lett 243(2): 202-210, 2006.
4. Trafalis DT, Geromichalos GD, Bountouroglou N, Koumbi D, Kontos M, Sougias D, Dalezis P, Karamanakos P, Papageorgiou A, Camoutsis C and Athanassiou AE: A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma. J BUON 10(2): 227-234, 2005. (Pubitemid 41320565)
5. Papageorgiou A, Lialiaris T, Stergiou E, Stergiou I, Tsigris C, Kourti A, Geromichalos G, Stravoravdi P, Trafalis D, Athanassiou AE, Pitsas A and Camoutsis Ch: Preclinical studies of steroid- linked nitrosoureas in murine pancreatic adenocarcinoma PAN02. J BUON 13(2): 235-239, 2008. (Pubitemid 351836707)
6. Trafalis DT, Tsavdaridis D, Camoutsis C, Karayiani V, Mourelatos D, Dalezis P, Athanassiou A, Pangalis GA and Papageorgiou A: Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia. Br J Haematol 128(3): 343-350, 2005. (Pubitemid 40216156)
7. Trafalis DT, Sambani C, Kapsimali V, Economidou J, Politis T and Catsoulacos P: Effects of homo-aza-steroids on acute non-lymphocytic leukaemia cell proliferation in vitro. Br J Haematol 91(4): 907-914, 1995.
8. Trafalis DT, Camoutsis C and Papageorgiou A: Research on the anti-tumour effect of steroid lactam alkylator (NSC-294859) in comparison with conventional chemotherapeutics in malignant melanoma. Melanoma Res 15(4): 273-281, 2005. (Pubitemid 41127463)
9. Kontos M, Nikolopoulou M, Trafalis DT, Geromichalos GD, Koukoulitsa C, Camoutsis JC, Bastounis E and Karamanakos P: The effect of an estrone D-lactam steroid ester derivative on breast cancer cells and its predicted binding interactions with the ligand-binding domain of estrogen receptor-alpha. Oncol Res 16(3): 129-142, 2005.
10. Trafalis DT, Camoutsis C, Karamanakos P, Arvanitis A, Tegou E, Ziras N and Athanassiou AE: Preclinical evaluation of the homo-aza-steroid ester 13beta-hydroxy-13alpha-amino-13,17- seco-5alpha-androstan-17-oic-13,17-lactam-p- bis(2-chloroethyl) aminophenoxy acetate for the treatment of malignant melanoma. J BUON 8(4): 333-339, 2003. (Pubitemid 38660085)
11. Trafalis DT, Camoutsis C, Dalezis P, Papageorgiou A, Kontos M, Karamanakos P, Giannakos G and Athanassiou AE: Antitumour effect of A- and D-lactam androgen nitrogen mustards on non-small cell lung carcinoma. J BUON 9(3): 275-282, 2004.
12. Camoutsis C, Sambani C, Trafalis DT and Peristeris P: On the formation of steroidal amidoesters of 4-[N-N-bis(2-chloroethyl) amino]benzoic acid and their cytotoxic activity. Eur J Med Chem 34(7-8): 645-649, 1999.
13. Cao D, Russell RL, Zhang D, Leffert JJ and Pizzorno G: Uridine Phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62: 2313-2317, 2002. (Pubitemid 34411710)
14. Kawamura K, Takiguchi N, Wada A, Takenobu H, Kimura H, Soda H, Nagata M, Asano T and Tagawa M: Up-regulated expression of the uridine Phosphorylase gene in human gastric tumors is correlated with a favorable prognosis. Anticancer Res 26(6C): 4647-4651, 2006. (Pubitemid 46032094)
15. Matsusaka S, Yamasaki H, Fukushima M and Wakabayashi I: Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. Chemotherapy 53(1): 36-41, 2007. (Pubitemid 46143852)
16. Yan R, Wan L, Pizzorno G and Cao D: Uridine Phosphorylase in breast cancer: a new prognostic factor? Front Biosci 11: 2759-2766, 2006.
17. Roosild TP, Castronovo S, Fabbiani M and Pizzorno G: Implications of the structure of human uridine Phosphorylase 1 on the development of novel inhibitors for improving the therapeutic window of fluoropyrimidine chemotherapy. BMC Struct Biol 9: 14, 2009.
18. Cao D and Pizzorno G: Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today 40(5): 431-443, 2004. (Pubitemid 38858910)
19. Ligo M, Nishikata K, Nakajima Y, Szinai I, Veres Z, Szabolcs A and Clercq E: Differential effects of 2,2′-anhydro-5-ethyluridine, a uridine Phosphorylase inhibitor, on the antitumor activity of 5- fluorouridine and 5-fluoro-2′-deoxyuridine. Biochem Pharmacol 39: 1247-1253, 1990. (Pubitemid 20109242)
20. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR and Banerjee D: Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 8: 1037-1044, 2009.
21. Miyashita H, Takebayashi Y, Eliason JF, Fujimori F, Nitta Y, Sato A, Morikawa H, Ohashi A, Motegi K, Fukumoto M, Mori S and Uchida T: Uridine Phosphorylase is a potential prognostic factor in patients with oral squamous cell carcinoma. Cancer 94(11): 2959-2966, 2002. (Pubitemid 34547696)
22. Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe Si S, Miyashita H, Fukumoto M, Toi M and Uchida T: Expression of uridine and thymidine Phosphorylase genes in human breast carcinoma. Int J Cancer 97(5): 631-635, 2002. (Pubitemid 34087802)
23. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6(7): 412-422, 2009.
24. Sahin F, Qiu W, Wilentz RE, Iacobuzio-Donahue CA, Grosmark A and Su GH: RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium. Pancreas 30(2): 158-167, 2005.
25. Catsoulacos P and Wampler GL: Activity of 3β-hydroxy-13α- amino-13,17-seco-5α-androstane-17-oic-13,17-lactam(p-(bis(2- chloroethyl)amino) phenyl)acetate (NSC 290205) in murine solid tumors. Oncology 39: 109-112, 1982. (Pubitemid 12170238)
26. Catsoulacos P and Catsoulacos D: Hybrid anticancer compounds. Steroidal lactam esters of carboxylic derivatives of N,N-bis (2-chloroethyl) aniline. Anticancer Res 11(5): 1773-1777, 1991.
27. Catsoulacos P and Boutis L: Aza-steroids. Beckmann rearrangement of 3β-acetoxy-5α-androstan-17-one oxime acetate with boron fluoride. Alkylting agents. Chim Ther 8: 215-217, 1973.
28. Finlay GJ, Wilson WR and Baguley BC: Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol 22: 655-662, 1986.
29. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988. (Pubitemid 18056527)
30. Boyd MR and Pauli KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel Res 34: 91-109, 1995.
31. Martin DS, Stolti RL and Sawyer RC: Use of oral uridine as substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine Phosphorylase inhibitor 5- benzylacyclouridine. Cancer Chemother Pharmacol 24: 9-14, 1989. (Pubitemid 19139983)
32. al Safarjalani ON, Zhou XJ, Naguib FNM, Goudgaon NM, Schinazi RF and el Kouni MH: Modulation of the pharmacokinetics of endofenous plasma uridine by 5-(phenylrhio)acyclouridine, a uridine Phosphorylase inhibitor: implications for chemotherapy. Cancer Chemother Pharmacol 48: 145-150, 2001.
33. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The Protein Data Bank. Nucleic Acids Res 28: 235-242, 2000.
34. Berman HM, Henrick K and Nakamura H: Announcing the worldwide Protein Data Bank. Nature Struct Biol 10(12): 980, 2003. (Pubitemid 37500485)
35. Bernstein FC, Koetzle TF, Williams GJ, Meyer EE Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T and Tasumi M: The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 112(3): 535-542, 1977. (Pubitemid 8109216)
36. Kogan TP, Dupre B, Bui H, McAbee K, Kassir JM, Scott IL, Hu X, Vanderslice P, Beck PJ and Dixon RAF: Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6- bis[3-(3-carboxymethylphenyl) -4-(2-α-D-mannopyranosyloxy) phenyl]hexane (TBC1269). J Med Chem 41: 1099-1111, 1998. (Pubitemid 28207386)
37. DeLano WL: The PyMOL Molecular Graphics System 0.99, DeLano Scientific, San Carlos, CA, USA, 2006.
38. Papageorgiou A, Andreadis Ch, Boutis A, Lialiaris Th and Mouratidou D: NSC 290205-based therapy in murine pancreatic adenocarcinoma PAN02 in combination with adriamycin ADR. Anticancer Res 26: 243-248, 2006.
39. Catsoulacos P: Further studies on the anti-neoplastic activity of 3 β-hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13, 17-lactam {p-[bis(2-chloroethyl)amino]-phenyl}acetate (NSC 290205). Cancer Lett 22(2): 199-202, 1984.
40. Wampler G and Catsoulacos P: Antileukemic effect of homo aza-steroidal ester of [p-[bis(2-chloroethyl)amino]phenyl]acetic acid. Cancer Treat Rep 61(1): 37-41, 1977. (Pubitemid 8100653)
41. Mourelatos D, Petrou C, Boutis L, Papageorgiou A, Catsoulacos P and Dozi-Vassiliades J: Induction of cytogenetic damage by modified steroidal derivatives of p-bis(2-chloroethyl) aminophenylacetic acid in human lymphocytes. Mutat Res 190(3): 205-210, 1987. (Pubitemid 17020129)